SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Caplin Point Laboratories informs about press release

28 Mar 2024 Evaluate
Caplin Point Laboratories has attached a Press Release regarding grant of final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Ketorolac tromethamine Ophthalmic Solution 0.5% (eye drops), to its Subsidiary Caplin Steriles.

The above information is a part of company’s filings submitted to BSE.

Caplin Point Labs. Share Price

2528.95 -33.20 (-1.30%)
02-Jul-2026 14:15 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1871.45
Dr. Reddys Labs. 1357.40
Cipla 1454.00
Zydus Lifesciences 1098.20
Lupin 2397.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: